Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
RELY-30
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
- NCT02917083 ↗
- Recruiting
- Baylor College of Medicine
- Focused
We haven't built an HCP commentary report on RELY-30 (relapsed CD30 expressing lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RELY-30 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- Phase I Study of Relapsed CD30 Expressing Lymphoma Treated With CD30 CAR T Cells (RELY-30)
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Hodgkin's Lymphoma; Non-Hodgkin Lymphoma
- Interventions
- CAR T Cells
- Arms
- CD30.CAR T Cells · Experimental
- Enrollment
- 60 (estimated)
- Primary outcomes
- Number of Patients with Dose-Limiting Toxicities (DLT)
- Sponsor
- Baylor College of Medicine with The Methodist Hospital Research Institute
- Start
- May 8, 2017
- Primary completion
- Apr 2027 (estimated)
- Results posted
- No
- Registry record
- NCT02917083 · updated Oct 2, 2026
Publications
linked from the registry- Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo B. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 Nov 10;38(32):3794-3804. doi: 10.1200/JCO.20.01342. Epub 2020 Jul 23. PubMed 32701411